These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27305409)

  • 21. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply.
    Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
    Aliment Pharmacol Ther; 2017 May; 45(10):1372. PubMed ID: 28417494
    [No Abstract]   [Full Text] [Related]  

  • 22. Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough?
    Allocca M; Fiorino G; Danese S
    Dig Dis Sci; 2017 Nov; 62(11):2964-2965. PubMed ID: 28776140
    [No Abstract]   [Full Text] [Related]  

  • 23. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.
    Annese V; Vecchi M;
    Dig Liver Dis; 2014 Nov; 46(11):963-8. PubMed ID: 25139379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.
    Danese S; Fiorino G; Raine T; Ferrante M; Kemp K; Kierkus J; Lakatos PL; Mantzaris G; van der Woude J; Panes J; Peyrin-Biroulet L
    J Crohns Colitis; 2017 Jan; 11(1):26-34. PubMed ID: 27927718
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA approves biosimilar version of infliximab.
    Traynor K
    Am J Health Syst Pharm; 2016 May; 73(10):604-6. PubMed ID: 27147206
    [No Abstract]   [Full Text] [Related]  

  • 27. Infliximab biosimilar CT-P13 in Crohn's disease.
    Gecse KB; D'Haens GR
    Lancet; 2019 Apr; 393(10182):1671-1672. PubMed ID: 30929894
    [No Abstract]   [Full Text] [Related]  

  • 28. The switch to infliximab biosimilars.
    Veselý R; Richardson P
    Lancet; 2017 Jun; 389(10086):2266-2268. PubMed ID: 28502608
    [No Abstract]   [Full Text] [Related]  

  • 29. Biosimilars in dermatology: starting with infliximab.
    Puig L
    Actas Dermosifiliogr; 2013 Apr; 104(3):175-80. PubMed ID: 23218608
    [No Abstract]   [Full Text] [Related]  

  • 30. A review of CT-P13: an infliximab biosimilar.
    McKeage K
    BioDrugs; 2014 Jun; 28(3):313-21. PubMed ID: 24723086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Current situations and the future prospect of monoclonal antibody products].
    Yamaguchi T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):36-46. PubMed ID: 25707201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IBD: To switch or not to switch: that is the biosimilar question.
    Danese S; Peyrin-Biroulet L
    Nat Rev Gastroenterol Hepatol; 2017 Sep; 14(9):508-509. PubMed ID: 28676708
    [No Abstract]   [Full Text] [Related]  

  • 33. New contributions to consensus on biosimilars.
    Argüelles-Arias F; Barreiro-de-Acosta M; Carballo F; Hinojosa J; Tejerina T
    Rev Esp Enferm Dig; 2014 Mar; 106(3):228-9. PubMed ID: 25007024
    [No Abstract]   [Full Text] [Related]  

  • 34. A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia.
    Brodszky V; Rencz F; Péntek M; Baji P; Lakatos PL; Gulácsi L
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):119-25. PubMed ID: 26162458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients.
    Fiorino G; Correale C; Radice S; Allocca M; Furfaro F; Gilardi D; Nagore D; Del Rio L; Pascual J; Martínez A; Danese S
    Aliment Pharmacol Ther; 2017 Nov; 46(9):903-905. PubMed ID: 29023889
    [No Abstract]   [Full Text] [Related]  

  • 37. Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply.
    Komaki Y; Yamada A; Komaki F; Sakuraba A
    Aliment Pharmacol Ther; 2017 Nov; 46(9):905-906. PubMed ID: 29023885
    [No Abstract]   [Full Text] [Related]  

  • 38. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CT-P13 (Inflectra™, Remsima™) monitoring in patients with inflammatory bowel disease.
    Schulze K; Koppka N; Lutter F; Brandhorst G; Schreiber S; Helwig U
    Biologicals; 2016 Sep; 44(5):463-6. PubMed ID: 27435444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.